Verastem Inc (VSTM)

01:30 AM

What are Verastem Inc. company’s key revenue driversRapid profit acceleration - jammulinksnews.com

01:30 AM

01:06 AM

Is Verastem Inc. stock overvalued or undervaluedExplosive capital appreciation - jammulinksnews.com

01:06 AM

03:02 AM

Why Verastem Inc. stock attracts strong analyst attentionFast Moving Stock Alerts - Metal.it

03:02 AM

Jul 25, 2025

What drives Verastem Inc. stock priceUnstoppable profit momentum - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer - Targeted Oncology

Jul 25, 2025

Jul 25, 2025

Verastem Inc. Stock Analysis and ForecastRapid capital growth - PrintWeekIndia

Jul 25, 2025

Jul 25, 2025

Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - BioSpace

Jul 25, 2025

Jul 24, 2025

What analysts say about Verastem Inc. stockFree Market Dynamics Reports - Autocar Professional

Jul 24, 2025

Jul 24, 2025

Is Verastem Inc. a good long term investmentAccelerated earnings growth - Autocar Professional

Jul 24, 2025

Jul 24, 2025

Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks

Jul 24, 2025

Jul 24, 2025

Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest

Jul 24, 2025

Jul 24, 2025

Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha

Jul 24, 2025

Jul 24, 2025

Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma

Jul 24, 2025

Jul 24, 2025

FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada

Jul 24, 2025

Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve

Jul 23, 2025

Jul 23, 2025

High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga

Jul 23, 2025

Jul 22, 2025

(VSTM) Proactive Strategies - news.stocktradersdaily.com

Jul 22, 2025

Jul 18, 2025

Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks

Jul 18, 2025

Jul 16, 2025

Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha

Jul 16, 2025

Jul 15, 2025

What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser

Jul 15, 2025

Jul 15, 2025

How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser

Jul 15, 2025

Jul 14, 2025

Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest

Jul 14, 2025

Jul 14, 2025

Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance

Jul 14, 2025

Jul 11, 2025

Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest

Jul 11, 2025

Jul 11, 2025

Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada

Jul 11, 2025

Jul 11, 2025

Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com

Jul 11, 2025